胸腺肽α1对稳定期支气管扩张患者症状控制及免疫功能的影响

目的探讨胸腺肽α1对稳定期支气管扩张患者急性加重的预防作用及对细胞免疫的影响。方法将73例稳定期支气管扩张患者随机分为治疗组和对照组,治疗组除常规予支气管舒张剂及祛痰治疗外,给予胸腺肽a1 1.6 mg皮下注射,每周2次,共3个月,对照组仅予常规予支气管舒张剂及祛痰治疗,两组均随访9月,观察两组患者在临床症状控制表现并检测治疗前后患者外周血淋巴细胞亚群分布及血清IL-2和IFN-γ水平。结果胸腺肽α1组患者在症状控制表现上优于对照组,需住院治疗人次亦减少(P<0.05);胸腺肽α1组患者3个月后外周血CD4+、CD4+/CD8+比例上升(P<0.05),IL-2和IFN-γ浓度升高(P<0.05);对照组前后无明显变化(P>0.05)。结论胸腺肽a1通过增强稳定期支气管扩张患者的细胞免疫功能,可减少支气管扩张患者的急性加重频率。

The effecte of thymosin alpha 1 on symptoms and immune activity of the stable stage of the patients with bronchiectasis

Objective To investigate the effects of thymosin alpha 1 on the prevention and cellular immune activity of the stable stage of the patients with bronchiectasis.Methods 73 patients with bronchiectasis in the stable stage were randomly divided into treatment and control groups.The two groups were given conventional treatment of eliminating sputum,meanwhile,the treatment group was received thymosin alpha 1 1.6 mg hypodermic injection,2 times per week for 3 months.All patients were followed for 9 months.The clinical symptoms of patients were assessed after 9 months treatment.Before treatment and 9 months after treatment,the expression of IL-2 and IFN-r in the serum of two groups were measured,and the blood samples were collected for the measurement of the lyphmocyte subset.Results After 3 month treatment of thymosin alpha 1,the clinical symptoms of treatment group more significantly improved than those of the control group.The numbers of patients suffered from acute exacerbation in hospital were significantly lower than those of the control group.Serum CD4 and CD4/CD8 levels of the treatment group were significantly increased(P<0.05).The expression of INF-r and IL-2 in the treatment groups were significantly improved after treatment without significant difference between the two groups.Conclusion Thymosin alpha 1 in the treatment of the stable stage of ronchiectasis can improve cellular immune activity and decrease the frequency of acute exacerbation of bronchiectasis.